Tetsuya Mitsudomi
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Oncology top 0.02%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
Papers in
-
- Lung Cancer Treatments and Mutations 283
- Lung Cancer Diagnosis and Treatment 105
- Oncology 197
- Lung Cancer Research Studies 68
- Colorectal Cancer Treatments and Studies 44
- HER2/EGFR in Cancer Research 27
- Cancer-related Molecular Pathways 25
- Co-authors
- Yasushi Yatabe (132 shared papers)Takashi Takahashi (53 shared papers)Takayuki Kosaka (35 shared papers)Hideki Endoh (12 shared papers)Kenichi Suda (99 shared papers)Toyoaki Hida (39 shared papers)Hiroyuki Kuwano (22 shared papers)Hirotaka Osada (14 shared papers)
- Journals
- Journal of Thoracic Oncology (55 papers)Lung Cancer (49 papers)Journal of Clinical Oncology (46 papers)Cancer Science (20 papers)Cancer Research (19 papers)
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Tetsuya Mitsudomi
512 papers receiving 37.0k citations
Tetsuya Mitsudomi's Hit Papers
Peers
Comparison fields: 5 of 161
- Pulmonary and Respiratory Medicine 20.3k
- Oncology 13.6k
- Cancer Research 7.2k
- Molecular Biology 13.0k
- Hepatology 1.1k
Countries citing papers authored by Tetsuya Mitsudomi
This map shows the geographic impact of Tetsuya Mitsudomi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tetsuya Mitsudomi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tetsuya Mitsudomi more than expected).
Fields of papers citing papers by Tetsuya Mitsudomi
This network shows the impact of papers produced by Tetsuya Mitsudomi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tetsuya Mitsudomi. The network helps show where Tetsuya Mitsudomi may publish in the future.
Co-authors
The 25 scholars most cited alongside Tetsuya Mitsudomi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 531 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Hit paper breakdown → | 2007 | 3694 |
| 2 | Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival Hit paper breakdown → | 2004 | 2022 |
| 3 | Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer Hit paper breakdown → | 2004 | 1063 |
| 4 | EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors Hit paper breakdown → | 2010 | 955 |
| 5 | Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence Hit paper breakdown → | 2005 | 845 |
| 6 | Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial Hit paper breakdown → | 2022 | 844 |
| 7 | Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Hit paper breakdown → | 1998 | 751 |
| 8 | Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations Hit paper breakdown → | 2008 | 528 |
| 9 | Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study Hit paper breakdown → | 2016 | 511 |
| 10 | Reduced expression of Dicer associated with poor prognosis in lung cancer patients Hit paper breakdown → | 2005 | 505 |
| 11 | Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib Hit paper breakdown → | 2006 | 492 |
| 12 | 2007 | 490 | |
| 13 | A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201) Hit paper breakdown → | 2011 | 477 |
| 14 | Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. | 1990 | 474 |
| 15 | Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer Hit paper breakdown → | 2009 | 453 |
| 16 | 1992 | 405 | |
| 17 | 2002 | 325 | |
| 18 | 2016 | 323 | |
| 19 | Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial Hit paper breakdown → | 2019 | 319 |
| 20 | Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. | 1999 | 286 |
About Tetsuya Mitsudomi
Tetsuya Mitsudomi is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Surgery, having authored 531 papers that have together received 38.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (283 papers), Lung Cancer Diagnosis and Treatment (105 papers), Lung Cancer Research Studies (68 papers), Colorectal Cancer Treatments and Studies (44 papers), Cancer Genomics and Diagnostics (37 papers), RNA modifications and cancer (35 papers), HER2/EGFR in Cancer Research (27 papers) and Cancer-related Molecular Pathways (25 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (20.3k citations), Oncology (13.6k citations), Cancer Research (7.2k citations), Molecular Biology (13.0k citations) and Hepatology (1.1k citations). Tetsuya Mitsudomi has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Yasushi Yatabe, Takashi Takahashi, Takayuki Kosaka, Hideki Endoh, Kenichi Suda, Toyoaki Hida, Hiroyuki Kuwano, Hirotaka Osada, Yoshihisa Kobayashi and Shuta Tomida. Their work appears in journals such as Journal of Thoracic Oncology, Lung Cancer, Journal of Clinical Oncology, Cancer Science and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.